Skip to content
Triangle logo TriangleGet started
← Full study record

NCT05824689 · OUTCOME

Prevalence of FRE

Fluoroquinolone Resistance Prevalence Study · Source last updated 2026-06-05

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
Duration between Apheresis Consultation and Day +100

What was measured

Prevalence of FRE in patients undergoing autologous PBSC transplantation with dose-intense melphalan

Analysis population: Based on Samples Provided at Specific Timepoints

Groups in this outcome

Enrolled Participants

Subjects eligible for this study will meet the defined eligibility criteria to undergo autologous transplantation established at the transplant centers as per standard of care (SOC). All adult patients with a diagnosis of multiple myeloma undergoing autologous transplantation after dose-intense melphalan conditioning are candidates for enrollment into this study. These subjects will be approached for enrollment into this study by the transplant attending physician caring for the patient

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Enrolled Participants117

Reported measurements

Pre-CDE mobilization

Analysis denominator · Participants

GroupSource count
Enrolled Participants47
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Enrolled Participants11Not reportedNot reportedNot reportedNot reported
Pre-transplant

Analysis denominator · Participants

GroupSource count
Enrolled Participants117
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Enrolled Participants23Not reportedNot reportedNot reportedNot reported
Hosp discharge

Analysis denominator · Participants

GroupSource count
Enrolled Participants98
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Enrolled Participants29Not reportedNot reportedNot reportedNot reported
Day 100

Analysis denominator · Participants

GroupSource count
Enrolled Participants92
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Enrolled Participants28Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        11
    denoms
    1. counts
      1. group Id
        OG000
        value
        47
      units
      Participants
    title
    Pre-CDE mobilization
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        23
    denoms
    1. counts
      1. group Id
        OG000
        value
        117
      units
      Participants
    title
    Pre-transplant
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        29
    denoms
    1. counts
      1. group Id
        OG000
        value
        98
      units
      Participants
    title
    Hosp discharge
  4. categories
    1. measurements
      1. group Id
        OG000
        value
        28
    denoms
    1. counts
      1. group Id
        OG000
        value
        92
      units
      Participants
    title
    Day 100
denoms
  1. counts
    1. group Id
      OG000
      value
      117
    units
    Participants
description
Prevalence of FRE in patients undergoing autologous PBSC transplantation with dose-intense melphalan
groups
  1. description
    Subjects eligible for this study will meet the defined eligibility criteria to undergo autologous transplantation established at the transplant centers as per standard of care (SOC). All adult patients with a diagnosis of multiple myeloma undergoing autologous transplantation after dose-intense melphalan conditioning are candidates for enrollment into this study. These subjects will be approached for enrollment into this study by the transplant attending physician caring for the patient
    id
    OG000
    title
    Enrolled Participants
param Type
COUNT_OF_PARTICIPANTS
population Description
Based on Samples Provided at Specific Timepoints
reporting Status
POSTED
time Frame
Duration between Apheresis Consultation and Day +100
title
Prevalence of FRE
type
PRIMARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice